Kangstem Biotech Co. Ltd Cash Flow-to-Debt Ratio
Kangstem Biotech Co. Ltd cash flow-to-debt ratio. Kangstem Biotech Co. Ltd (217730) has a Cash Flow-to-Debt Ratio of -0.42x as of June 2026, meaning its operating cash flow of ₩-4.93 Billion could theoretically repay 0% of its total liabilities (₩11.86 Billion) in one year. Check Kangstem Biotech Co. Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kangstem Biotech Co. Ltd (2015–2025)
Cash flow-to-debt ratio of Kangstem Biotech Co. Ltd from 2015 to 2025. Historical debt coverage capacity for Kangstem Biotech Co. Ltd across 11 annual periods. Check 217730 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Kangstem Biotech Co. Ltd Cash Flow-to-Debt Ratio by Year (2015–2025)
Kangstem Biotech Co. Ltd cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Kangstem Biotech Co. Ltd. For the full cash flow conversion analysis, see 217730 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | ₩-11.68 Billion | ₩12.43 Billion | ▲ +36.7% |
| 2024 | -1.48x | ₩-18.99 Billion | ₩12.80 Billion | ▼ -230.2% |
| 2023 | -0.45x | ₩-16.50 Billion | ₩36.74 Billion | ▲ +20.6% |
| 2022 | -0.57x | ₩-18.86 Billion | ₩33.33 Billion | ▼ -16.8% |
| 2021 | -0.48x | ₩-16.99 Billion | ₩35.07 Billion | ▼ -6.9% |
| 2020 | -0.45x | ₩-13.99 Billion | ₩30.89 Billion | ▼ -46.0% |
| 2019 | -0.31x | ₩-13.32 Billion | ₩42.92 Billion | ▲ +31.0% |
| 2018 | -0.45x | ₩-11.48 Billion | ₩25.50 Billion | ▲ +5.2% |
| 2017 | -0.47x | ₩-10.65 Billion | ₩22.44 Billion | ▼ -48.9% |
| 2016 | -0.32x | ₩-7.80 Billion | ₩24.46 Billion | ▲ +68.6% |
| 2015 | -1.01x | ₩-3.80 Billion | ₩3.75 Billion | — |